ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $39.00

ArriVent BioPharma (NASDAQ:AVBP) had its price target upped by equities research analysts at HC Wainwright from $36.00 to $39.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 54.09% from the stock’s current price.

ArriVent BioPharma Stock Up 3.7 %

Shares of ArriVent BioPharma stock opened at $25.31 on Wednesday. ArriVent BioPharma has a 12-month low of $14.35 and a 12-month high of $36.37. The stock has a 50 day moving average price of $27.11 and a two-hundred day moving average price of $25.96.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AVBP. Charles Schwab Investment Management Inc. boosted its holdings in ArriVent BioPharma by 153.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock valued at $4,756,000 after acquiring an additional 122,641 shares during the period. Geode Capital Management LLC lifted its position in shares of ArriVent BioPharma by 154.2% during the 3rd quarter. Geode Capital Management LLC now owns 597,165 shares of the company’s stock worth $14,036,000 after purchasing an additional 362,221 shares during the last quarter. Barclays PLC boosted its stake in ArriVent BioPharma by 1,124.8% during the 3rd quarter. Barclays PLC now owns 41,522 shares of the company’s stock valued at $976,000 after purchasing an additional 38,132 shares during the period. State Street Corp grew its holdings in ArriVent BioPharma by 210.4% in the 3rd quarter. State Street Corp now owns 476,809 shares of the company’s stock valued at $11,205,000 after buying an additional 323,186 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in ArriVent BioPharma by 32.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,965 shares of the company’s stock worth $516,000 after buying an additional 5,397 shares during the period. Institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.